Literature DB >> 36043417

L-2-Hydroxyglutarate Protects Against Cardiac Injury via Metabolic Remodeling.

Huamei He1, Ryan M Mulhern1, William M Oldham1, Wusheng Xiao1, Yi-Dong Lin1, Ronglih Liao1, Joseph Loscalzo1.   

Abstract

BACKGROUND: L-2-hydroxyglutarate (L2HG) couples mitochondrial and cytoplasmic energy metabolism to support cellular redox homeostasis. Under oxygen-limiting conditions, mammalian cells generate L2HG to counteract the adverse effects of reductive stress induced by hypoxia. Very little is known, however, about whether and how L2HG provides tissue protection from redox stress during low-flow ischemia (LFI) and ischemia-reperfusion injury. We examined the cardioprotective effects of L2HG accumulation against LFI and ischemia-reperfusion injury and its underlying mechanism using genetic mouse models. METHODS AND
RESULTS: L2HG accumulation was induced by homozygous (L2HGDH [L-2-hydroxyglutarate dehydrogenase]-/-) or heterozygous (L2HGDH+/-) deletion of the L2HGDH gene in mice. Hearts isolated from these mice and their wild-type littermates (L2HGDH+/+) were subjected to baseline perfusion and 90-minute LFI or 30-minute no-flow ischemia followed by 60- or 120-minute reperfusion. Using [13C]- and [31P]-NMR (nuclear magnetic resonance) spectroscopy, high-performance liquid chromatography, reverse transcription quantitative reverse transcription polymerase chain reaction, ELISA, triphenyltetrazolium staining, colorimetric/fluorometric spectroscopy, and echocardiography, we found that L2HGDH deletion induces L2HG accumulation at baseline and under stress conditions with significant functional consequences. In response to LFI or ischemia-reperfusion, L2HG accumulation shifts glucose flux from glycolysis towards the pentose phosphate pathway. These key metabolic changes were accompanied by enhanced cellular reducing potential, increased elimination of reactive oxygen species, attenuated oxidative injury and myocardial infarction, preserved cellular energy state, and improved cardiac function in both L2HGDH-/- and L2HGDH+/- hearts compared with L2HGDH+/+ hearts under ischemic stress conditions.
CONCLUSION: L2HGDH deletion-induced L2HG accumulation protects against myocardial injury during LFI and ischemia-reperfusion through a metabolic shift of glucose flux from glycolysis towards the pentose phosphate pathway. L2HG offers a novel mechanism for eliminating reactive oxygen species from myocardial tissue, mitigating redox stress, reducing myocardial infarct size, and preserving high-energy phosphates and cardiac function. Targeting L2HG levels through L2HGDH activity may serve as a new therapeutic strategy for cardiovascular diseases related to oxidative injury.

Entities:  

Keywords:  L-2-hydroxyglutarate dehydrogenase; glycolysis; ischemia; oxidative stress; pentose phosphate pathway; reactive oxygen species; reperfusion injury

Mesh:

Substances:

Year:  2022        PMID: 36043417      PMCID: PMC9533473          DOI: 10.1161/CIRCRESAHA.122.321227

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   23.213


  30 in total

Review 1.  Mitochondrial catalase and oxidative injury.

Authors:  J Bai; A I Cederbaum
Journal:  Biol Signals Recept       Date:  2001 May-Aug

2.  Simultaneous determination of lactate and pyruvate in human sweat using reversed-phase high-performance liquid chromatography: a noninvasive approach.

Authors:  Simona Biagi; Silvia Ghimenti; Massimo Onor; Emilia Bramanti
Journal:  Biomed Chromatogr       Date:  2012-02-07       Impact factor: 1.902

3.  Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy.

Authors:  P B Garlick; M J Davies; D J Hearse; T F Slater
Journal:  Circ Res       Date:  1987-11       Impact factor: 17.367

Review 4.  Pathophysiology of ischaemia-reperfusion injury.

Authors:  D L Carden; D N Granger
Journal:  J Pathol       Date:  2000-02       Impact factor: 7.996

5.  L-2-hydroxyglutaric aciduria: identification of ten novel mutations in the L2HGDH gene.

Authors:  J O Sass; F Jobard; M Topçu; A Mahfoud; E Werlé; S Cure; N Al-Sannaa; S A Alshahwan; M Bataillard; L Cimbalistiene; C Grolik; V Kemmerich; H Omran; L Sztriha; M Tabache; J Fischer
Journal:  J Inherit Metab Dis       Date:  2008-04-14       Impact factor: 4.982

6.  A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model.

Authors:  Kazuhiro Nagaoka; Tetsuya Matoba; Yajing Mao; Yasuhiro Nakano; Gentaro Ikeda; Shizuka Egusa; Masaki Tokutome; Ryoji Nagahama; Kaku Nakano; Kenji Sunagawa; Kensuke Egashira
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

7.  Hypoxia Induces Production of L-2-Hydroxyglutarate.

Authors:  Andrew M Intlekofer; Raymond G Dematteo; Sriram Venneti; Lydia W S Finley; Chao Lu; Alexander R Judkins; Ariën S Rustenburg; Patrick B Grinaway; John D Chodera; Justin R Cross; Craig B Thompson
Journal:  Cell Metab       Date:  2015-07-23       Impact factor: 31.373

Review 8.  Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning.

Authors:  Theodore Kalogeris; Yimin Bao; Ronald J Korthuis
Journal:  Redox Biol       Date:  2014-06-02       Impact factor: 11.799

9.  A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair.

Authors:  Rim Rzem; Younes Achouri; Etienne Marbaix; Olivier Schakman; Elsa Wiame; Sandrine Marie; Philippe Gailly; Marie-Françoise Vincent; Maria Veiga-da-Cunha; Emile Van Schaftingen
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

10.  Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.

Authors:  Sudeshna Fisch; Noa Bachner-Hinenzon; Offir Ertracht; Liang Guo; Yhara Arad; Danny Ben-Zvi; Ronglih Liao; Jacob Schneiderman
Journal:  J Am Heart Assoc       Date:  2020-05-07       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.